InvestorsHub Logo
Followers 40
Posts 3318
Boards Moderated 0
Alias Born 08/18/2009

Re: midastouch017 post# 1184

Friday, 10/06/2017 9:43:06 AM

Friday, October 06, 2017 9:43:06 AM

Post# of 3881
And a translation to English by a computer. I prefer to go with the original English quotes from the company's own PR where their enthusiasm is strong.

"We are greatly encouraged by the top-line results"
"demonstrated a very good safety profile in this study as well as impressive efficacy"
"While not powered for statistical significance of the secondary efficacy endpoints, the study suggested clinically meaningful improvement in both secondary efficacy endpoints of abdominal pain response and overall response "
"The secondary efficacy endpoints results also compared favorably to the absolute difference observed for these endpoints in reported studies of Xifaxan and Viberzi"

As has been said, this is still only a PII, but this emerging biotech company has so many arrows in its quiver, and is starting to generate revenue with commercialized products today, that IMO it's one of the best (de-risked + huge potential) investments around today, for the long-term value investor.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News